A
Auctapharma
Innovative branded specialty pharmaceuticals enhancing proven molecules for better patient outcomes
About Auctapharma
Aucta Pharmaceuticals, Inc. is a technology-driven company specializing in the development and commercialization of branded specialty pharmaceutical products. Operating within the pharmaceutical industry, Aucta focuses on creating improved therapeutics by enhancing proven molecules through the 505(b)(2) regulatory pathway. This pathway allows the company to develop new dosage forms, dosing regimens, and indications for existing drugs, thereby accelerating the time to market and reducing development costs.
Aucta serves a diverse range of clients, including healthcare providers, hospitals, and pharmacies, primarily targeting therapeutic areas such as Central Nervous System (CNS) disorders, dermatology, and pediatrics. The company's business model revolves around innovation and patient-centric solutions, aiming to improve drug delivery and efficacy. Revenue is generated through the sale of these branded specialty products, leveraging their robust pipeline to meet market demands.
Source: Dealroom company dataAt a glance
- Founded
- 2012
- Headquarters
- Pudong, China
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Department of Health and Human Services
Series A4 investors entered at this stage
Cowin Venture
Sangel Capital- GCGrand Yangtze Capital
- TMTianjin Haida Venture Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Auctapharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Auctapharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.